Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,731,178 shares, an increase of 57.6% from the February 15th total of 1,733,391 shares. Based on an average daily trading volume, of 6,663,905 shares, the short-interest ratio is currently 0.4 days. Approximately 8.4% of the company’s shares are sold short.
Several research analysts have recently commented on the company. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a report on Monday. Roth Capital assumed coverage on Anthera Pharmaceuticals in a report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $4.38.
Large investors have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new position in Anthera Pharmaceuticals during the 4th quarter valued at about $399,000. Armistice Capital LLC purchased a new position in Anthera Pharmaceuticals during the 4th quarter valued at about $1,269,000. Finally, BVF Inc. IL increased its holdings in Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after purchasing an additional 209,896 shares during the period. Institutional investors own 28.12% of the company’s stock.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. analysts forecast that Anthera Pharmaceuticals will post -1.75 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Anthera Pharmaceuticals Inc (ANTH) Sees Significant Increase in Short Interest” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/03/14/anthera-pharmaceuticals-inc-anth-sees-significant-increase-in-short-interest.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.